68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer
Purpose We aimed at evaluating the role of 68 Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer. Methods A total of 142 patients with biochemical recurrence of prostate cancer...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2018-10, Vol.45 (11), p.1862-1872 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1872 |
|---|---|
| container_issue | 11 |
| container_start_page | 1862 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 45 |
| creator | Schmidkonz, Christian Cordes, Michael Schmidt, Daniela Bäuerle, Tobias Goetz, Theresa Ida Beck, Michael Prante, Olaf Cavallaro, Alexander Uder, Michael Wullich, Bernd Goebell, Peter Kuwert, Torsten Ritt, Philipp |
| description | Purpose
We aimed at evaluating the role of
68
Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer.
Methods
A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [
68
Ga]Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). Quantitative assessment of all 641
68
Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values. All PET-derived parameters were tested for correlation with serum PSA levels and for association with Gleason scores.
In 23 patients who underwent
68
Ga-PSMA-11 PET/CT before and after therapy with either external beam radiation, androgen deprivation, or docetaxel chemotherapy, SUVmax and TL-PSMA were compared to radiographic response assessment of CT images based on RECIST 1.1 criteria and to biochemical response determined by changes of serum PSA levels.
Results
PSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (
P
|
| doi_str_mv | 10.1007/s00259-018-4042-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2035245121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2034091934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c279t-3f6ca0448e996b1029f28ee790df870860a834abb51905f4872d5d3c9f7d687d3</originalsourceid><addsrcrecordid>eNp1kd9KHTEQxpdSoVZ9AO8C3vQmOslmd5NLOVgrKAo9XofsZtKu7CbHJNuiL-Brm8MRC0KvZgZ-3_z7quqYwSkD6M4SAG8UBSapAMHp86dqn7VM0Q6k-vyed_Cl-prSAxSQS7VfvbTy0tC7nzfnlDFyd7E-W62pxTj-QUtmzKYP0ziQjYmmVBgTcSESu03n0Zs8Bk-CI39_hwlpH-wTyctciH6JFj0x3pIc0eQZfSYR0yb4hGT0ZBNDyiYjGYwfMB5We85MCY_e4kF1__1ivfpBr28vr1bn13Tgncq0du1gQAiJSrU9A64cl4idAutkObUFI2th-r5hChonZMdtY-tBuc62srP1QfVt17fMf1wwZT2PacBpMh7DkjSHuuGiYZwV9OQD-hCW6Mt2W0qAYqoWhWI7aigHpYhOb-I4m_ikGeitNXpnjS4f11tr9HPR8J0mFdb_wviv8_9Fr9EEkZM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2034091934</pqid></control><display><type>article</type><title>68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer</title><source>SpringerLink Journals - AutoHoldings</source><creator>Schmidkonz, Christian ; Cordes, Michael ; Schmidt, Daniela ; Bäuerle, Tobias ; Goetz, Theresa Ida ; Beck, Michael ; Prante, Olaf ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</creator><creatorcontrib>Schmidkonz, Christian ; Cordes, Michael ; Schmidt, Daniela ; Bäuerle, Tobias ; Goetz, Theresa Ida ; Beck, Michael ; Prante, Olaf ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</creatorcontrib><description>Purpose
We aimed at evaluating the role of
68
Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer.
Methods
A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [
68
Ga]Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). Quantitative assessment of all 641
68
Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values. All PET-derived parameters were tested for correlation with serum PSA levels and for association with Gleason scores.
In 23 patients who underwent
68
Ga-PSMA-11 PET/CT before and after therapy with either external beam radiation, androgen deprivation, or docetaxel chemotherapy, SUVmax and TL-PSMA were compared to radiographic response assessment of CT images based on RECIST 1.1 criteria and to biochemical response determined by changes of serum PSA levels.
Results
PSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (
P
< 0.0001) and TL-PSMA was significantly different for different Gleason scores. The agreement rate between TL-PSMA derived from PET and biochemical response was 87% (95% confidence interval, 0.66–0.97; Cohen’s κ = 0.78;
P
< 0.01) and, thus, higher than for SUVmax, which was 74% (95% CI, 0.52–0.90; κ = 0.55;
P
< 0.01). Furthermore, agreement with PSA was higher for TL-PSMA and SUVmax than for CT-based response evaluation. Discordant findings between PET and CT were most likely due to limitations of CT and RECIST in rating small lymph nodes as metastases, as well as bone involvement, which was sometimes not detectable in CT.
Conclusion
68
Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. Especially, TL-PSMA demonstrated higher agreement rates with biochemical response compared to SUVmax. Larger, ideally prospective trials are needed to help to reveal the full potential of metabolic parameters derived from PET imaging with
68
Ga-PSMA-11.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-018-4042-z</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biochemistry ; Cancer therapies ; Cardiology ; Chemotherapy ; Clinical trials ; Computed tomography ; Confidence intervals ; Deprivation ; Evaluation ; Field of view ; Imaging ; Lesions ; Lymph nodes ; Medicine ; Medicine & Public Health ; Metabolism ; Metastases ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Parameters ; Patients ; Positron emission ; Prostate cancer ; Radiation ; Radiology ; Tomography ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2018-10, Vol.45 (11), p.1862-1872</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c279t-3f6ca0448e996b1029f28ee790df870860a834abb51905f4872d5d3c9f7d687d3</citedby><cites>FETCH-LOGICAL-c279t-3f6ca0448e996b1029f28ee790df870860a834abb51905f4872d5d3c9f7d687d3</cites><orcidid>0000-0002-1988-0058</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-018-4042-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-018-4042-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Cordes, Michael</creatorcontrib><creatorcontrib>Schmidt, Daniela</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><creatorcontrib>Goetz, Theresa Ida</creatorcontrib><creatorcontrib>Beck, Michael</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Cavallaro, Alexander</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><title>68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
We aimed at evaluating the role of
68
Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer.
Methods
A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [
68
Ga]Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). Quantitative assessment of all 641
68
Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values. All PET-derived parameters were tested for correlation with serum PSA levels and for association with Gleason scores.
In 23 patients who underwent
68
Ga-PSMA-11 PET/CT before and after therapy with either external beam radiation, androgen deprivation, or docetaxel chemotherapy, SUVmax and TL-PSMA were compared to radiographic response assessment of CT images based on RECIST 1.1 criteria and to biochemical response determined by changes of serum PSA levels.
Results
PSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (
P
< 0.0001) and TL-PSMA was significantly different for different Gleason scores. The agreement rate between TL-PSMA derived from PET and biochemical response was 87% (95% confidence interval, 0.66–0.97; Cohen’s κ = 0.78;
P
< 0.01) and, thus, higher than for SUVmax, which was 74% (95% CI, 0.52–0.90; κ = 0.55;
P
< 0.01). Furthermore, agreement with PSA was higher for TL-PSMA and SUVmax than for CT-based response evaluation. Discordant findings between PET and CT were most likely due to limitations of CT and RECIST in rating small lymph nodes as metastases, as well as bone involvement, which was sometimes not detectable in CT.
Conclusion
68
Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. Especially, TL-PSMA demonstrated higher agreement rates with biochemical response compared to SUVmax. Larger, ideally prospective trials are needed to help to reveal the full potential of metabolic parameters derived from PET imaging with
68
Ga-PSMA-11.</description><subject>Biochemistry</subject><subject>Cancer therapies</subject><subject>Cardiology</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Computed tomography</subject><subject>Confidence intervals</subject><subject>Deprivation</subject><subject>Evaluation</subject><subject>Field of view</subject><subject>Imaging</subject><subject>Lesions</subject><subject>Lymph nodes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Parameters</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Prostate cancer</subject><subject>Radiation</subject><subject>Radiology</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kd9KHTEQxpdSoVZ9AO8C3vQmOslmd5NLOVgrKAo9XofsZtKu7CbHJNuiL-Brm8MRC0KvZgZ-3_z7quqYwSkD6M4SAG8UBSapAMHp86dqn7VM0Q6k-vyed_Cl-prSAxSQS7VfvbTy0tC7nzfnlDFyd7E-W62pxTj-QUtmzKYP0ziQjYmmVBgTcSESu03n0Zs8Bk-CI39_hwlpH-wTyctciH6JFj0x3pIc0eQZfSYR0yb4hGT0ZBNDyiYjGYwfMB5We85MCY_e4kF1__1ivfpBr28vr1bn13Tgncq0du1gQAiJSrU9A64cl4idAutkObUFI2th-r5hChonZMdtY-tBuc62srP1QfVt17fMf1wwZT2PacBpMh7DkjSHuuGiYZwV9OQD-hCW6Mt2W0qAYqoWhWI7aigHpYhOb-I4m_ikGeitNXpnjS4f11tr9HPR8J0mFdb_wviv8_9Fr9EEkZM</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Schmidkonz, Christian</creator><creator>Cordes, Michael</creator><creator>Schmidt, Daniela</creator><creator>Bäuerle, Tobias</creator><creator>Goetz, Theresa Ida</creator><creator>Beck, Michael</creator><creator>Prante, Olaf</creator><creator>Cavallaro, Alexander</creator><creator>Uder, Michael</creator><creator>Wullich, Bernd</creator><creator>Goebell, Peter</creator><creator>Kuwert, Torsten</creator><creator>Ritt, Philipp</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></search><sort><creationdate>20181001</creationdate><title>68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer</title><author>Schmidkonz, Christian ; Cordes, Michael ; Schmidt, Daniela ; Bäuerle, Tobias ; Goetz, Theresa Ida ; Beck, Michael ; Prante, Olaf ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c279t-3f6ca0448e996b1029f28ee790df870860a834abb51905f4872d5d3c9f7d687d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biochemistry</topic><topic>Cancer therapies</topic><topic>Cardiology</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Computed tomography</topic><topic>Confidence intervals</topic><topic>Deprivation</topic><topic>Evaluation</topic><topic>Field of view</topic><topic>Imaging</topic><topic>Lesions</topic><topic>Lymph nodes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Parameters</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Prostate cancer</topic><topic>Radiation</topic><topic>Radiology</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Cordes, Michael</creatorcontrib><creatorcontrib>Schmidt, Daniela</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><creatorcontrib>Goetz, Theresa Ida</creatorcontrib><creatorcontrib>Beck, Michael</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Cavallaro, Alexander</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidkonz, Christian</au><au>Cordes, Michael</au><au>Schmidt, Daniela</au><au>Bäuerle, Tobias</au><au>Goetz, Theresa Ida</au><au>Beck, Michael</au><au>Prante, Olaf</au><au>Cavallaro, Alexander</au><au>Uder, Michael</au><au>Wullich, Bernd</au><au>Goebell, Peter</au><au>Kuwert, Torsten</au><au>Ritt, Philipp</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><date>2018-10-01</date><risdate>2018</risdate><volume>45</volume><issue>11</issue><spage>1862</spage><epage>1872</epage><pages>1862-1872</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
We aimed at evaluating the role of
68
Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer.
Methods
A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [
68
Ga]Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). Quantitative assessment of all 641
68
Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values. All PET-derived parameters were tested for correlation with serum PSA levels and for association with Gleason scores.
In 23 patients who underwent
68
Ga-PSMA-11 PET/CT before and after therapy with either external beam radiation, androgen deprivation, or docetaxel chemotherapy, SUVmax and TL-PSMA were compared to radiographic response assessment of CT images based on RECIST 1.1 criteria and to biochemical response determined by changes of serum PSA levels.
Results
PSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (
P
< 0.0001) and TL-PSMA was significantly different for different Gleason scores. The agreement rate between TL-PSMA derived from PET and biochemical response was 87% (95% confidence interval, 0.66–0.97; Cohen’s κ = 0.78;
P
< 0.01) and, thus, higher than for SUVmax, which was 74% (95% CI, 0.52–0.90; κ = 0.55;
P
< 0.01). Furthermore, agreement with PSA was higher for TL-PSMA and SUVmax than for CT-based response evaluation. Discordant findings between PET and CT were most likely due to limitations of CT and RECIST in rating small lymph nodes as metastases, as well as bone involvement, which was sometimes not detectable in CT.
Conclusion
68
Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. Especially, TL-PSMA demonstrated higher agreement rates with biochemical response compared to SUVmax. Larger, ideally prospective trials are needed to help to reveal the full potential of metabolic parameters derived from PET imaging with
68
Ga-PSMA-11.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00259-018-4042-z</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2018-10, Vol.45 (11), p.1862-1872 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2035245121 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biochemistry Cancer therapies Cardiology Chemotherapy Clinical trials Computed tomography Confidence intervals Deprivation Evaluation Field of view Imaging Lesions Lymph nodes Medicine Medicine & Public Health Metabolism Metastases Nuclear Medicine Oncology Original Article Orthopedics Parameters Patients Positron emission Prostate cancer Radiation Radiology Tomography Tumors |
| title | 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A56%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=68Ga-PSMA-11%20PET/CT-derived%20metabolic%20parameters%20for%20determination%20of%20whole-body%20tumor%20burden%20and%20treatment%20response%20in%20prostate%20cancer&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Schmidkonz,%20Christian&rft.date=2018-10-01&rft.volume=45&rft.issue=11&rft.spage=1862&rft.epage=1872&rft.pages=1862-1872&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-018-4042-z&rft_dat=%3Cproquest_cross%3E2034091934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2034091934&rft_id=info:pmid/&rfr_iscdi=true |